ABSTRACT
Palmar and plantar fibromatoses are disease processes in which the presence of certain growth factors has not been defined. Monoclonal antibodies against transforming growth factor-beta, epidermal growth factor, procollagen type 1, fibronectin, phosphotyrosine residues, and CD41 platelet antigen were used in standard immunoperoxidase staining to study 36 nodules and 24 cords obtained from patients with fibromatoses. The specimens were studied via light microscopy, and staining intensity was quantitated using a computer-enhanced video system. Transforming growth factor-beta staining paralleled procollagen I, fibronectin, and phosphotyrosine staining within the nodule (early stages) but not the cord (late stages) tissue. These factors showed significant increased staining in the early stage of fibromatosis when compared to the late stage. This study is a preliminary demonstration of the presence of transforming growth factor-beta in palmar and plantar fibromatoses.
Subject(s)
Fibroma/chemistry , Foot Dermatoses/metabolism , Growth Substances/analysis , Hand Dermatoses/metabolism , Adult , Epidermal Growth Factor/analysis , Female , Fibroma/pathology , Fibronectins/analysis , Foot Dermatoses/pathology , Hand Dermatoses/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Phosphotyrosine , Procollagen/analysis , Transforming Growth Factor beta/analysis , Tyrosine/analogs & derivatives , Tyrosine/analysisABSTRACT
An experimental model was developed combining arterial trauma with island flap creation using the rat groin flap system. Flap arteries were subjected to crush/avulsion injuries with subsequent microvascular repair. A second series involved resection 4 hr after thrombosis of injured flap arteries and interpositional vein grafting to reestablish circulation. A single bolus of systemic heparin was administered to half of the animals from each series on a blinded, randomized basis. Arterial patency at 7 days correlated with flap survival. There was no case of partial flap loss. Patencies improved in the first series from 31% to 71% with heparin administration (P less than 0.05) and from 58% to 90% in the second (not significantly different). A third series involving immediate resection of traumatized vessel and vein graft replacement achieved a patency of 92% (without heparinization). These results support the value of replacement of all traumatized arterial tissue with vein grafts and indicate the efficacy of systemic heparin (in single bolus) for enhancing the likelihood of maintaining patency. Furthermore, it is suggested that the occurrence of a thrombogenic site in the arterial inflow to a region of dependent tissue does not lead to partial tissue loss, and thus thromboembolic events may not be responsible for this clinical phenomenon.
Subject(s)
Femoral Artery/injuries , Graft Survival , Heparin/therapeutic use , Skin Transplantation/methods , Skin/blood supply , Surgical Flaps , Anastomosis, Surgical , Animals , Femoral Artery/surgery , Graft Occlusion, Vascular/surgery , Groin , Male , Microsurgery , Necrosis , Rats , Rats, Inbred Strains , Regional Blood Flow , Thigh/blood supply , Thrombosis/surgery , Time Factors , Vascular Patency , Veins/transplantationABSTRACT
The results of this study demonstrate the existence of molecular heterogeneity (polymorphism) within DR beta-chains isolated from a single serologically defined DR phenotype, DR4. The data are consistent with the possibility that this polymorphism is related to the Dw/LD phenotype as defined with the cellular reagents, homozygous typing cells.